In a report released on January 4, Jailendra Singh from Truist Financial maintained a Hold rating on Teladoc (TDOC – Research Report), with a price target of $23.00. The company’s shares closed last Friday at $21.40.
According to TipRanks, Singh is an analyst with an average return of -15.2% and a 33.54% success rate. Singh covers the Healthcare sector, focusing on stocks such as R1 RCM, Evolent Health, and Agilon Health.
In addition to Truist Financial, Teladoc also received a Hold from BTIG’s David Larsen in a report issued on January 5. However, on January 2, Barclays initiated coverage with a Buy rating on Teladoc (NYSE: TDOC).
See today’s best-performing stocks on TipRanks >>
TDOC market cap is currently $3.54B and has a P/E ratio of -0.87.
Based on the recent corporate insider activity of 79 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TDOC in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Teladoc (TDOC) Company Description:
Teladoc Health, Inc. is a multinational telemedicine and virtual healthcare company. The company provides telehealth solutions, expert medical services, medical opinions, artificial intelligence and analytics, behavioral health solutions, guidance and support, and platform and program services.
Read More on TDOC:
